Cancer Research and Biotechnology AG (CRB) is a Swiss biopharma company developing a novel small molecule treatments effective in pancreatic c., triple-negative breast c., and colon cancer. CRB091 is non-toxic, targeting triple-negative breast cancer (TNBC). First in-human submission in 2025.

Products, services, technology

CRB091, oncology, late preclinical. The CRB team has identified a root cause or amplifier of many human cancers. This constitutes the first step towards a safer effective curative and protective method to treat cancer patients. Pancreatic cancer, triple-negative breast cancer, and colon cancer.

Cooperation possibilities

Funding: Non-toxic cancer drugs on fast-to-market regulatory pathway. Shown effective against deadly cancers with high unmet medical need )TNBC, CRC, and PC). Next first in-human studies on a fast track.
Research: Therapeutic agents affecting the mitochondrial metabolic pathways.
Out-licensing: TNBC

Some insights
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
  • Number of employees in Switzerland

You may also be interested in